Once these data are confirmed in larger and prospective cohorts of CM patients bearing BMs, our results could underly that elevated LDH levels identify an aggressive subset of brain metastatic CM that should be oriented to IT-based therapy regardless of BRAF mutational status. Here, BRAF is linked to cutaneous mastocytosis.